This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peters, U. R. Articles by Schmidt, C. A. Search for Related Content PubMed PubMed Citation Articles by Peters, U. R. Articles by Schmidt, C. A.

Distinct Expression Patterns of the p53-Homologue p73 in Malignant and Normal Hematopoiesis Assessed by a Novel Real-Time Reverse Transcription-Polymerase Chain Reaction Assay and Protein Analysis¹

Department of Hematology/Oncology, Charité/Virchow-Clinic, Humboldt-University, 13353 Berlin, Germany [U. R. P., K. A. K., G. B., U. L, C. A. S.], and Department of Clinical Research, University and Inselspital Berne, 3010 Berne, Switzerland [M. P. T., A. T., M. F. F.]

The role of the recently identified first p53-homologue, p73, in neoplastic transformation is unknown. To elucidate p73 gene expression in hematopoiesis, we investigated samples from chronic myeloid leukemia (CML) and acute myeloid leukemia patients, leukemia cell lines, as well as mature and immature normal hematopoietic cells by real-time quantitative RT-PCR and Western blot analysis. We found a distinct p73 expression profile with highest p73 mRNA transcript levels in hematopoietic malignancies such as CML blast crisis and acute myelogenous leukemia versus CML chronic phase and normal controls. Mono- and biallelic p73 expression was found in both normal and malignant hematopoiesis. p73 protein was expressed at various levels in leukemia samples and cell lines but could not be detected in any normal controls tested. Our results point to a distinct yet undefined role of p73 in the pathogenesis of myeloid neoplasms.

This article has been cited by other articles:

				M. Komor, S. Guller, C. D. Baldus, S. de Vos, D. Hoelzer, O. G. Ottmann, and W.-K. Hofmann Transcriptional Profiling of Human Hematopoiesis During In Vitro Lineage-Specific Differentiation Stem Cells, September 1, 2005; 23(8): 1154 - 1169. [Abstract] [Full Text] [PDF]

				U. M. Moll and N. Slade p63 and p73: Roles in Development and Tumor Formation Mol. Cancer Res., July 1, 2004; 2(7): 371 - 386. [Abstract] [Full Text] [PDF]

				A Oniscu, N Sphyris, R G Morris, S Bader, and D J Harrison p73{alpha} is a candidate effector in the p53 independent apoptosis pathway of cisplatin damaged primary murine colonocytes J. Clin. Pathol., May 1, 2004; 57(5): 492 - 498. [Abstract] [Full Text] [PDF]

				S. Das, W. S. El-Deiry, and K. Somasundaram Regulation of the p53 Homolog p73 by Adenoviral Oncogene E1A J. Biol. Chem., May 9, 2003; 278(20): 18313 - 18320. [Abstract] [Full Text] [PDF]

				W.-K. Hofmann, S. de Vos, M. Komor, D. Hoelzer, W. Wachsman, and H. P. Koeffler Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow Blood, November 15, 2002; 100(10): 3553 - 3560. [Abstract] [Full Text] [PDF]

				W.-K. Hofmann, S. de Vos, K. Tsukasaki, W. Wachsman, G. S. Pinkus, J. W. Said, and H. P. Koeffler Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray Blood, August 1, 2001; 98(3): 787 - 794. [Abstract] [Full Text] [PDF]

				A. Zaika, M. Irwin, C. Sansome, and U. M. Moll Oncogenes Induce and Activate Endogenous p73 Protein J. Biol. Chem., March 30, 2001; 276(14): 11310 - 11316. [Abstract] [Full Text] [PDF]